Molecular Cancer Therapeutics CTRC-AACR San Antonio Breast Cancer Symposium
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
Vol. 1, 1366, December 2002     Molecular Cancer Therapeutics
© 2002 American Association for Cancer Research

Erratum

In the article by Simeone et al., entitled "A Novel Mechanism by Which N-(4-hydroxyphenyl)retinamide Inhibits Breast Cancer Cell Growth: The Production of Nitric Oxide," which appeared in the October 2002 issue of MCT (pp. 1009–1017), Figure 7 appeared in black and white but should have appeared in color as seen below. The authors do, however, possess reprints that include the correct color version of the figure.



View larger version (90K):
[in this window]
[in a new window]
[Download PPT slide]
 
Fig. 7. NOSII expression was increased when 4-HPR was combined with IFN-{gamma} or TAM. T47D cells were plated (1 x 105 cells/well) in 6-well plates in DMEM/F12 medium supplemented with 5% FBS. Cells were treated with 4-HPR (1 µM) alone or in combination with IFN-{gamma} (50 IU/ml) or TAM (1 µM). Cells treated with 4-HPR alone or in combination with TAM were incubated for 5 days, and cells treated with a combination of 4-HPR and IFN-{gamma} were incubated for 4 days. Cells were harvested and immunostained for NOS isoforms. A, NOSII immunostainings; B, NOSIII immunostainings. Untreated (i); 1 µM 4-HPR (ii); IFN-{gamma} (iii); IFN-{gamma} and 4-HPR (iv); TAM; (v); TAM and 4-HPR (vi).

 





This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online